Rep. Lisa C. McClain Sells Illumina, Inc. (NASDAQ:ILMN) Shares

Representative Lisa C. McClain (R-Michigan) recently sold shares of Illumina, Inc. (NASDAQ:ILMN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Illumina stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Illumina Stock Up 2.9%

NASDAQ ILMN traded up $3.68 on Tuesday, hitting $129.64. 1,586,895 shares of the stock traded hands, compared to its average volume of 2,160,662. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average of $105.72 and a 200 day moving average of $98.01. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The company has a market capitalization of $19.81 billion, a P/E ratio of 16.41, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm posted $1.14 EPS. The company’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Illumina

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rise Advisors LLC grew its stake in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares in the last quarter. Quent Capital LLC acquired a new position in Illumina in the third quarter worth approximately $29,000. Quarry LP bought a new position in shares of Illumina in the third quarter valued at $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Illumina during the 3rd quarter valued at $33,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Royal Bank Of Canada set a $124.00 price objective on shares of Illumina in a report on Tuesday, September 2nd. TD Cowen raised their price target on shares of Illumina from $110.00 to $115.00 and gave the company a “hold” rating in a research note on Friday, October 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Evercore ISI increased their price objective on Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Daiwa America downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $115.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.